231 related articles for article (PubMed ID: 30876800)
21. MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma.
Han Z; Estephan RJ; Wu X; Su C; Yuan YC; Qin H; Kil SH; Morales C; Schmolze D; Sanchez JF; Tian L; Yu J; Kortylewski M; Rosen ST; Querfeld C
J Invest Dermatol; 2022 Mar; 142(3 Pt A):603-612.e7. PubMed ID: 34774537
[TBL] [Abstract][Full Text] [Related]
22. miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.
Xia L; Wu L; Xia H; Bao J; Li Q; Chen X; Xia R
Cell Cycle; 2019 Jul; 18(14):1635-1645. PubMed ID: 31213131
[TBL] [Abstract][Full Text] [Related]
23. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma.
Wu K; Lund M; Bang K; Thestrup-Pedersen K
Cancer; 1999 Sep; 86(6):1056-63. PubMed ID: 10491534
[TBL] [Abstract][Full Text] [Related]
24. Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside.
Damsky WE; Choi J
Curr Treat Options Oncol; 2016 Jul; 17(7):33. PubMed ID: 27262707
[TBL] [Abstract][Full Text] [Related]
25. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA Signatures in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma.
Shen X; Wang B; Li K; Wang L; Zhao X; Xue F; Shi R; Zheng J
J Invest Dermatol; 2018 Sep; 138(9):2024-2032. PubMed ID: 29559342
[TBL] [Abstract][Full Text] [Related]
27. Expression of miR-155 and miR-126 in situ in cutaneous T-cell lymphoma.
Kopp KL; Ralfkiaer U; Nielsen BS; Gniadecki R; Woetmann A; Ødum N; Ralfkiaer E
APMIS; 2013 Nov; 121(11):1020-4. PubMed ID: 24033365
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
Kohnken R; Kodigepalli KM; Mishra A; Porcu P; Wu L
Leuk Res; 2017 Jan; 52():58-66. PubMed ID: 27889686
[TBL] [Abstract][Full Text] [Related]
29. Multi-Kinase Inhibitor with Anti-p38γ Activity in Cutaneous T-Cell Lymphoma.
Zhang XH; Nam S; Wu J; Chen CH; Liu X; Li H; McKeithan T; Gong Q; Chan WC; Yin HH; Yuan YC; Pillai R; Querfeld C; Horne D; Chen Y; Rosen ST
J Invest Dermatol; 2018 Nov; 138(11):2377-2387. PubMed ID: 29758280
[TBL] [Abstract][Full Text] [Related]
30. Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.
Gaydosik AM; Tabib T; Geskin LJ; Bayan CA; Conway JF; Lafyatis R; Fuschiotti P
Clin Cancer Res; 2019 Jul; 25(14):4443-4454. PubMed ID: 31010835
[TBL] [Abstract][Full Text] [Related]
31. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma.
Kopp KL; Ralfkiaer U; Gjerdrum LM; Helvad R; Pedersen IH; Litman T; Jønson L; Hagedorn PH; Krejsgaard T; Gniadecki R; Bonefeld CM; Skov L; Geisler C; Wasik MA; Ralfkiaer E; Ødum N; Woetmann A
Cell Cycle; 2013 Jun; 12(12):1939-47. PubMed ID: 23676217
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
33. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.
Yumeen S; Mirza FN; Lewis JM; King ALO; Kim SR; Carlson KR; Umlauf SR; Surovtseva YV; Foss FM; Girardi M
Blood Adv; 2020 May; 4(10):2213-2226. PubMed ID: 32437546
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma.
Sandoval J; Díaz-Lagares A; Salgado R; Servitje O; Climent F; Ortiz-Romero PL; Pérez-Ferriols A; Garcia-Muret MP; Estrach T; Garcia M; Nonell L; Esteller M; Pujol RM; Espinet B; Gallardo F
J Invest Dermatol; 2015 Apr; 135(4):1128-1137. PubMed ID: 25405321
[TBL] [Abstract][Full Text] [Related]
35. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.
Nicolay JP; Müller-Decker K; Schroeder A; Brechmann M; Möbs M; Géraud C; Assaf C; Goerdt S; Krammer PH; Gülow K
Blood; 2016 Aug; 128(6):805-15. PubMed ID: 27268084
[TBL] [Abstract][Full Text] [Related]
36. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.
Lai P; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):34-51. PubMed ID: 33628583
[TBL] [Abstract][Full Text] [Related]
37. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells.
Marzec M; Halasa K; Kasprzycka M; Wysocka M; Liu X; Tobias JW; Baldwin D; Zhang Q; Odum N; Rook AH; Wasik MA
Cancer Res; 2008 Feb; 68(4):1083-91. PubMed ID: 18281483
[TBL] [Abstract][Full Text] [Related]
38. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
[TBL] [Abstract][Full Text] [Related]
39. Current status of cutaneous T-cell lymphoma: molecular diagnosis, pathogenesis, therapy and future directions.
Dippel E; Klemke CD; Goerdt S
Onkologie; 2003 Oct; 26(5):477-83. PubMed ID: 14605466
[TBL] [Abstract][Full Text] [Related]
40. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
